Paper Search Console

Home Search Page About Contact

Journal Title

Title of Journal: Neurol Sci

Search In Journal Title:

Abbravation: Neurological Sciences

Search In Journal Abbravation:

Publisher

Springer Milan

Search In Publisher:

DOI

10.1007/bf03016991

Search In DOI:

ISSN

1590-3478

Search In ISSN:
Search In Title Of Papers:

Motor outcomes in patients with advanced Parkinson

Authors: Leonardo Lopiano Nicola Modugno Pietro Marano Mariachiara Sensi Giuseppe Meco Antonino Cannas Graziano Gusmaroli Filippo Tamma Francesca Mancini Rocco Quatrale Anna Maria Costanzo Giuliana Gualberti Gabriella Melzi Umberto di Luzio Paparatti Angelo Antonini
Publish Date: 2016/07/15
Volume: 37, Issue: 11, Pages: 1785-1792
PDF Link

Abstract

Several levodopa/carbidopa intestinal gel LCIG studies showed a significant reduction of OFF time and a significant increase of ON time as well as a reduction of dyskinesia and improvement of nonmotor symptoms and quality of life However few studies have been conducted in a large population for more than 3 years Interim outcomes from GREENFIELD observational study on a large Italian cohort of advanced PD patients who started LCIG in routine care between 2007 and 2014 still on treatment at the enrollment are presented Comparison between baseline before LCIG start and visit 1 at enrollment is reported Primary endpoint was Unified Parkinson’s Disease Rating Scale UPDRS IV Item 39 secondary endpoints were UPDRS I and II as outcome of quality of life Overall 145 of 148 enrolled patients from 14 Movement Disorder Centers in Italy were evaluable with a mean LCIG treatment period of 138 ± 166 years at enrollment Compared with baseline the mean score regarding daily time spent in OFF UPDRS IV Item 39 at visit 1 significantly decreased from 21 ± 08 to 09 ± 07 57  reduction vs baseline P  00001 UPDRS IV improved by 39  P  00001 scores for dyskinesia duration and disability were reduced by 28  18 ± 10–13 ± 09 P  00001 and 33  15 ± 11 to 10 ± 10 P  00001 respectively and the scores for painful dyskinesia and early morning dystonia were reduced by 56  09 ± 10–04 ± 07 P  00001 and 25  04 ± 05–03 ± 05 P  0001 respectively The preliminary results of this interim analysis support the efficacy of LCIG on motor complications and activities of daily livingParkinson’s disease PD is a chronic progressive neurodegenerative disorder characterized by motor impairments tremor rigidity bradykinesia and postural instability 1 Further features include nonmotor symptoms such as cognitive dysfunction depression and sleep disorders 1 2 resulting in reduced quality of life 3 and negative effects on social interactions 3 4 Moreover patients with PD have a progressive loss of autonomy with a consequent impact on caregiver quality of lifeAs the disease progresses the response duration to levodopa shortens and the therapeutic window narrows resulting in unpredictable fluctuations with random and sudden ‘‘OFF’’ periods as well as disabling dyskinesia which exert a negative impact on the overall daily activities and quality of life 5 Motor and nonmotor symptoms reflect fluctuations in levodopa plasma concentrations due to the short halflife of levodopa and erratic absorption in relation with delayed gastric emptying 6Continuous dopaminergic drug delivery obtained with the administration of intraduodenal levodopa/carbidopa intestinal gel LCIG has been shown to provide a more stable plasma concentration of levodopa in patients with nonoptimal control of motor fluctuations 7 A number of studies have shown that LCIG leads to a significant reduction of OFF time and a significant increase of ON time as well as a reduction of dyskinesias 8 9 10 11 In addition improvements in nonmotor symptoms—and quality of life—were observed 12 13 However few studies have been conducted in a large population of patients with PD to assess the longterm outcome over a period of 2 years of treatment with LCIG 14 15 Therefore the aim of this observational study was to evaluate the clinical outcomes of a large Italian cohort of patients with advanced PD receiving LCIG in routine clinical care to evaluate the effects of therapy on both motor and nonmotor symptoms and the related impact on patient quality of life and caregiver burden from the initiation of LCIG therapy over a maximum exposure period of up to 9 years Here we present the interim results on motor symptoms and Unified Parkinson’s Disease Rating Scale UPDRS scores in this large cohort of patients with advanced PDInclusion criteria were being treated with LCIG the presence of adequate information about the previous medical history and treatment and the presence of at least one fulfilled scale or questionnaire among a selected list Patients could be enrolled at any time after LCIG treatment initiation Exclusion criteria were the presence of conditions that could have interfered with the longterm continuation of LCIG therapy at the physician’s discretion


Keywords:

References


.
Search In Abstract Of Papers:
Other Papers In This Journal:

  1. Increasing incidence of multiple sclerosis among women in Buenos Aires: a 22 year health maintenance organization based study
  2. Confusional state as first symptom of HaNDL syndrome
  3. Deep brain stimulation of the globus pallidus internal improves symptoms of chorea-acanthocytosis
  4. Terminal latency abnormality in amyotrophic lateral sclerosis without split hand syndrome
  5. The higher prevalence of non-right handers among patients with restless leg syndrome
  6. Neuromyelitis optica: atipic clinic presentation
  7. Role of matrix metalloproteinase-9 in apoptosis of hippocampal neurons in rats during early brain injury after subarachnoid hemorrhage
  8. Intravascular lymphomatosis and intracerebral haemorrhage
  9. Neurophysiological analysis of the cauda equina in POEMS syndrome
  10. How does the neck flexion affect the cervical MRI features of Hirayama disease?
  11. A case with anti-galactocerebroside antibody-positive Mycoplasma pneumoniae meningoencephalitis presenting secondary hypersomnia
  12. Serum prolidase activity and oxidative status in patients with diabetic neuropathy
  13. Can triptans safely be used for airplane headache?
  14. Multiple cranial nerve involvement in Bannwarth’s syndrome
  15. Role of neurostimulation in migraine
  16. Neuroprotective effect of apigenin in rats after contusive spinal cord injury
  17. Cranial Ewing’s sarcoma in children
  18. Comparisons of presentations and outcomes of neuromyelitis optica patients with and without Sjögren’s syndrome
  19. Chordoid meningioma: a retrospective series of seven consecutive cases
  20. Prevalence of headache in patients with Parkinson’s disease and its association with the side of motor symptom onset
  21. Dexamethasone suppression test, melatonin and TRH-test in cluster headache
  22. Post-natalizumab clinical and radiological findings in a cohort of multiple sclerosis patients: 12-month follow-up
  23. Anxiety state affects information processing speed in patients with multiple sclerosis
  24. Assessing executive function with the D-KEFS sorting test: normative data for a sample of the Italian adult population
  25. Psychiatric features in gelastic epilepsy and hypothalamic hamartoma: long-term psychodiagnostic observations
  26. Acute disseminated encephalomyelitis
  27. Induced neural stem cells have protective effects on cortical neuronal cells in vitro
  28. Clinical markers of therapeutic response to disease modifying drugs
  29. Striopallidodentate calcifications: nosographic, neuropathological and clinical proposal. Case report
  30. Major motor-functional determinants associated with poor self-reported health-related quality of life in myasthenia gravis patients
  31. Lambert-Eaton Myasthenic Syndrome presenting with a “dropped head syndrome” and associated with antibodies against N-type calcium channels
  32. Do the quantitative relationships of synaptic junctions and terminals in the thalamus of genetic absence epilepsy rats from Strasbourg (GAERS) differ from those in normal control Wistar rats
  33. Fatal Aspergillus brain abscess in immunocompetent patient
  34. The therapeutic future in headache
  35. Vitamin A and amygdala: functional and morphological consequences
  36. Carcinoma of the tongue and bulbar-onset amyotrophic lateral sclerosis: unusual differential diagnosis
  37. Effect of ACE inhibitors and AT 1 receptor antagonists on pentylenetetrazole-induced convulsions in mice
  38. The first Italian family with evidence of pyramidal impairment as phenotypic manifestation of Silver syndrome BSCL2 gene mutation
  39. Message from the Editor in Chief
  40. RETRACTED ARTICLE: Headaches and brain tumors
  41. Intestinal levodopa infusion: the Belgian experience
  42. Contact heat-evoked potentials as a useful means in patients with Guillain–Barré syndrome
  43. Contact heat-evoked potentials as a useful means in patients with Guillain–Barré syndrome
  44. The medial plantar and medial peroneal cutaneous nerve conduction studies for diabetic polyneuropathy
  45. Neurological pictures in Paediatric Chiari I malformation
  46. Contrast extravasation through MRI precedes cerebral hemorrhage in a patient with eclampsia
  47. Delayed posterior fossa epidural hematoma originating from occipital artery after infratentorial craniotomy
  48. The clock drawing test as a screening tool in mild cognitive impairment and very mild dementia: a new brief method of scoring and normative data in the elderly
  49. Neuropsychological assessment in myasthenia gravis
  50. Familial cerebral cavernous malformation: report of a further Italian family
  51. Fixed combination of cinnarizine and dimenhydrinate in the prophylactic therapy of vestibular migraine: an observational study
  52. Non-pharmacological management of migraine during pregnancy
  53. Cholinergic balance in dementia with Lewy bodies: reversible worsening of Parkinsonism at rivastigmine dosage modulation
  54. Chronic cerebro-spinal venous insufficiency (CCSVI) and multiple sclerosis
  55. α-Synuclein in the colon and premotor markers of Parkinson disease in neurologically normal subjects
  56. The combined treatment with orbital and pretarsal botulinum toxin injections in the management of poorly responsive blepharospasm
  57. Reversibility of brain lesions in a case of Neuro-Behçet’s disease studied by MR diffusion
  58. Speckled lentiginous nevus: sometimes, but not always, part of a syndrome
  59. Intracranial extraaxial ependymoma in children: a rare case report and review of the literature
  60. Tension-type headache in Parma’s adult general population: a focus on age of onset
  61. Pathological gambling plus hypersexuality in restless legs syndrome: a new case
  62. Headache with transient neurological deficit: a case report with hemispheric hypoperfusion and without lymphocytosis

Search Result: